OCS

Oculis Holding AG
CAPPED RATING

Oculis Holding AG, a clinical-stage biopharmaceutical company, develops novel topical treatments for ophthalmic diseases for both back- and front-of-the-eye. The company's lead candidate is OCS-01, a topical dexamethasone formulation, which is in Phase 3 clinical trials for the treatment of diabetic macular edema; OCS-02, a topical biologic candidate that is in Phase 2b clinical trials for the treatment for keratoconjunctivitis sicca, or dry eye disease; and OCS-05, a novel neuroprotective agent for acute optic neuritis and other neuro-ophtha disorders, such as glaucoma, diabetic retinopathy, geographic atrophy, and neurotrophic keratitis. The company is based in Zug, Switzerland.

Oculis Holding AG (OCS) is rated D+ (1.8/5) on Deltasharpe Prism, scored against Healthcare sector peers. Its strongest pillar is Profitability (C+); its weakest is Value (F).

Quantitative Factor Evaluation • Updated

Overall Rating
1.8 / 5.0
D+
Value
F
Factor Score 0.5 / 5.0
Growth
C
Factor Score 2.3 / 5.0
Profitability
C+
Factor Score 2.7 / 5.0
Momentum
D-
Factor Score 1.0 / 5.0
Revisions
C+
Factor Score 2.6 / 5.0

Prism grades are automated quantitative screens, not buy, sell or hold recommendations, and not investment advice. Data may be delayed or contain errors. Terms

Ratings of B- and above are for members.

Register free to see every rating — your first 2 weeks of Premium are on us.

Register — 2 weeks free

Underlying Financial Metrics

P/E Ratio -4.2
EV / EBITDA -2.8
Rev Growth YoY -97.1%
Gross Margin 0.0%
Price Return 3M -42.0%
Price Return 12M -61.3%
Catalyst Signal 0.00
Market Cap $417.9M
TTM Revenue $937.0K
Price / Sales 446.0
ROE -47.5%

Historical Factor Score Progression

Date Value Growth Profitability Momentum Revisions Overall
2026-11-13 F (0.5) C (2.3) C+ (2.7) D- (1.0) C+ (2.6) D+ (1.8)
2026-11-06 D- (0.8) C- (2.0) C- (2.0) D- (1.0) C+ (2.7) D+ (1.7)
2026-10-30 D- (0.7) B- (3.0) C (2.3) D (1.3) C+ (2.7) C- (2.0)
2026-10-23 F (0.7) B- (3.0) C (2.3) D (1.3) C+ (2.6) C- (2.0)
2026-10-16 D- (0.8) B- (3.0) C (2.3) D- (1.1) C+ (2.6) C- (2.0)
Page 1 of 3